These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19068958)

  • 1. Skin manifestations of diabetes.
    Van Hattem S; Bootsma AH; Thio HB
    Cleve Clin J Med; 2008 Nov; 75(11):772, 774, 776-7 passim. PubMed ID: 19068958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injection-site skin lesions following pen-injection treatment in a 59-year-old woman with insulin-treated Type 2 diabetes mellitus.
    Winkler G; Sápi Z; Pál B; Molnár L
    Diabet Med; 1997 Dec; 14(12):1078-9. PubMed ID: 9455937
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous manifestations of diabetes mellitus.
    Perez MI; Kohn SR
    J Am Acad Dermatol; 1994 Apr; 30(4):519-31; quiz 532-4. PubMed ID: 8157778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Skin changes in diabetes mellitus].
    Meurer M; Stumvoll M; Szeimies RM
    Hautarzt; 2004 May; 55(5):428-35. PubMed ID: 15083279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Manifestations of Diabetes Mellitus: A Review.
    Lima AL; Illing T; Schliemann S; Elsner P
    Am J Clin Dermatol; 2017 Aug; 18(4):541-553. PubMed ID: 28374407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Diabet Med; 2011 Mar; 28(3):276-86. PubMed ID: 21309835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cutaneous complications of insulin therapy. A drug-induced condition on the decline].
    Piérard-Franchimont C; Hermanns-Lê T; Scheen AJ; Piérard GE
    Rev Med Liege; 2005; 60(5-6):564-5. PubMed ID: 16035329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

  • 10. Where now for insulin glargine--a time for pragmatic medicine?
    Thomson GA; Craig R
    Int J Clin Pract; 2009 Oct; 63(10):1413-5. PubMed ID: 19689485
    [No Abstract]   [Full Text] [Related]  

  • 11. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
    Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
    Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiating basal insulin therapy in patients with type 2 diabetes mellitus.
    Stoneking K
    Am J Health Syst Pharm; 2005 Mar; 62(5):510-8. PubMed ID: 15745915
    [No Abstract]   [Full Text] [Related]  

  • 14. [Skin complications of diabetes mellitus therapy].
    Olsovský J
    Vnitr Lek; 2006 May; 52(5):474-6. PubMed ID: 16771093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatologic manifestations of diabetes mellitus: a review.
    Murphy-Chutorian B; Han G; Cohen SR
    Endocrinol Metab Clin North Am; 2013 Dec; 42(4):869-98. PubMed ID: 24286954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cutaneous stigmata of diabetes mellitus].
    Flagothier C; Quatresooz P; Bourguignon R; Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2005; 60(5-6):553-9. PubMed ID: 16035327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insulin treatment in type 2 diabetes].
    Birkeland KI
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):919-20. PubMed ID: 16554885
    [No Abstract]   [Full Text] [Related]  

  • 18. The diabetologist/cardiologist debate: a meeting of the minds.
    Mohamed F; Aalbers J
    Cardiovasc J Afr; 2012 Mar; 23(2):115-7. PubMed ID: 22447480
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin glargine: cornerstone treatment for type 2 diabetes patients. Introduction.
    Garg SK
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():1-4. PubMed ID: 18577151
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing the controversies of insulin therapy in patients with type 2 diabetes mellitus.
    Kuritzky L; Nelson SE
    J Fam Pract; 2005 Jun; 54(6):S3-6. PubMed ID: 16021782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.